•
Sep 30, 2022

ResMed Q1 2023 Earnings Report

ResMed's first quarter of fiscal year 2023 demonstrated revenue growth and solid performance.

Key Takeaways

ResMed Inc. reported a 5% increase in revenue to $950.3 million, with a diluted earnings per share of $1.43 and non-GAAP diluted earnings per share of $1.51.

Revenue increased by 5% to $950.3 million; up 9% on a constant currency basis.

Gross margin expanded by 90 bps to 56.9%; non-GAAP gross margin expanded by 40 bps to 57.6%.

Income from operations increased 5%; non-GAAP operating profit up 4%.

Diluted earnings per share of $1.43; non-GAAP diluted earnings per share of $1.51.

Total Revenue
$950M
Previous year: $904M
+5.1%
EPS
$1.51
Previous year: $1.51
+0.0%
Gross Profit
$541M
Previous year: $506M
+6.8%
Cash and Equivalents
$207M
Previous year: $276M
-25.0%
Free Cash Flow
$15.6M
Previous year: -$93M
-116.8%
Total Assets
$5.18B
Previous year: $4.73B
+9.5%

ResMed

ResMed

ResMed Revenue by Segment

ResMed Revenue by Geographic Location

Forward Guidance

No forward guidance was provided in the press release.